Alnylam Pharmaceuticals (ALNY) was downgraded by
Weiss Ratings from "hold (c-)" to "sell (d+)".
Alnylam Pharmaceuticals (ALNY) Presents Vutrisiran ATTR-CM Data at ACC.26 [Yahoo! Finance]
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up [Yahoo! Finance]
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management [Yahoo! Finance]
New Data Presented at ACC.26 Further Support Benefits of Vutrisiran in ATTR-CM and Potential of Zilebesiran for Hypertension Management